Search

everythinglearnresearchcommunity

for

Search:↓

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

Using 0.025% tretinoin may enhance minoxidil's effects for hair loss. Users suggest starting with 0.025% and gradually increasing the concentration, and discuss combining treatments like microneedling.

The conversation discusses the potential effectiveness and risks of using topical finasteride for hair loss, with considerations about using DMSO as a vehicle for application. Concerns are raised about DMSO's safety, absorption issues, and the systemic effects of topical finasteride.

Elevated bile acids can inhibit the enzyme AKR1C2, leading to increased DHT levels, which may accelerate hair loss in those predisposed to androgenetic alopecia. Treatments mentioned include topical minoxidil and finasteride.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

The user experienced hair improvement using a topical finasteride, minoxidil, and tretinoin combo, along with supplements like zinc, copper, magnesium, vitamin D3, K2, iodine, and boron. They believe these changes are due to addressing mineral deficiencies and possibly thyroid issues, despite skepticism from others.

A user made a 70/30 ethanol/propylene glycol topical finasteride solution but noticed chunks at the bottom. The discussion focuses on this issue with the DIY hair loss treatment.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

Using tretinoin or tazarotene with minoxidil may eliminate the need for microneedling or dermastamping. Microneedling can enhance minoxidil's effects but may cause long-term scalp issues.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

The conversation is about making topical finasteride using ethanol. The user is advised to use non-denatured or food-grade ethanol, as denatured ethanol may be harmful with prolonged skin exposure.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation discusses hair regrowth progress using Minoxidil, Biotin, Finasteride, and Ketoconazole, with microneedling stopped after 8 months. The user is questioning the effectiveness on temple areas after 1.7 years of treatment.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

A 32-year-old male with diffuse thinning and seborrheic dermatitis has been using finasteride for 8 months without improvement. He is considering COQ10 + PQQ supplements for scalp inflammation and hair loss.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.

A user ingested RU58841 orally and experienced severe heart and breathing issues, requiring emergency medical assistance. They concluded that MV supplements is a legitimate supplier but warned of the serious side effects.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The user experienced heart palpitations from using Fin (0.1%) and Min (10%) and is seeking alternatives. Options suggested include PRP or Mesotherapy, with a recommendation to try topical Fin without Min.

Topical Metformin shows potential for regenerating hair follicles and minimizing scarring in hair transplant donor areas, similar to Verteporfin but without its side effects. The discussion suggests considering Metformin for post-hair transplant care, though more human trials are needed.

Hair loss treatments like minoxidil, finasteride, TDM-105795, and PP405. MIT is hosting a hackathon to find innovative hair loss solutions.

Minoxidil may not be effective due to low sulfotransferase activity, and the user considers adding tretinoin to the regimen. They are unsure about the timing and combination with microneedling.

The user experienced positive hair regrowth using topical minoxidil, along with other factors like shorter hair, castor oil, and hair masks. The user is optimistic about further progress and wants to avoid baldness.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The user is using dutasteride, oral minoxidil, and topical minoxidil with tretinoin for hair loss. They are considering whether to continue this treatment or opt for a hair transplant for their temples.